Business Context and Reporting Period
This Form 8-K Current Report was filed by ProKidney Corp. on December 6, 2022, covering events occurring on December 2 and 3, 2022. The filing discloses the execution of new employment agreements with four key executive officers: the Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, and Senior Vice President, Global Head of Clinical Development and Interventional Procedures.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation arrangements. The following compensation details were disclosed:
| Executive | Role | Base Salary | Target Bonus |
|---|---|---|---|
| Timothy Bertram | CEO | $620,000 | 60% |
| James Coulston | CFO | $420,000 | 40% |
| Deepak Jain | COO | $495,000 | 45% |
| Joseph Stavas | SVP, Clinical Development | $560,000 | 40% |
Material Changes
The material change reported is the formalization of compensation terms for the company's top leadership. The agreements establish specific severance packages triggered by "Qualifying Terminations" (termination without Cause or resignation for Good Reason):
- Absent a Change in Control: Executives are eligible for base salary continuation ranging from 9 to 12 months and continued health plan participation.
- Following a Change in Control: Executives are eligible for lump-sum severance payments ranging from 1.0x to 1.5x the sum of their base salary and target bonus, plus full vesting of outstanding equity awards.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of general business risks. The primary contingency noted is the potential financial obligation to executives in the event of termination or a Change in Control. The text notes that the summary is qualified by the full text of the Employment Agreements, which will be filed as exhibits to the Form 10-K for the fiscal year ended December 31, 2022.
Investor Verification Checklist
- Verify the total annual cash compensation cost for the four executives based on the disclosed base salaries and target bonus percentages.
- Review the full Employment Agreements (to be filed in the 10-K) to understand the specific definitions of "Cause" and "Good Reason."
- Assess the potential liability for severance payments and equity acceleration in the event of a Change in Control.
- Confirm the company's cash position in upcoming filings to ensure it can meet these new fixed and contingent compensation obligations.